Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bioMerieux stock logo
BMXMF
bioMerieux
$142.45
$133.94
$93.50
$143.47
$16.86B0.738 shsN/A
Cencora, Inc. stock logo
COR
Cencora
$296.70
+1.5%
$289.70
$218.65
$309.35
$56.66B0.581.51 million shs1.65 million shs
Labcorp Holdings Inc. stock logo
LH
Labcorp
$257.12
-0.6%
$247.32
$198.96
$264.03
$21.65B0.81634,479 shs931,508 shs
Natera, Inc. stock logo
NTRA
Natera
$168.17
+2.4%
$158.53
$92.14
$183.00
$22.42B1.741.41 million shs1.44 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bioMerieux stock logo
BMXMF
bioMerieux
0.00%0.00%+9.80%+13.06%+42.51%
Cencora, Inc. stock logo
COR
Cencora
+1.64%-0.07%+1.19%+7.83%+25.00%
Labcorp Holdings Inc. stock logo
LH
Labcorp
-0.71%-1.70%+3.76%+11.91%+26.51%
Natera, Inc. stock logo
NTRA
Natera
+2.44%-1.64%+7.01%+16.83%+50.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bioMerieux stock logo
BMXMF
bioMerieux
N/AN/AN/AN/AN/AN/AN/AN/A
Cencora, Inc. stock logo
COR
Cencora
4.6078 of 5 stars
2.53.03.33.13.73.31.3
Labcorp Holdings Inc. stock logo
LH
Labcorp
4.5084 of 5 stars
2.43.02.54.23.42.51.3
Natera, Inc. stock logo
NTRA
Natera
2.0106 of 5 stars
2.52.00.00.02.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bioMerieux stock logo
BMXMF
bioMerieux
3.00
BuyN/AN/A
Cencora, Inc. stock logo
COR
Cencora
2.90
Moderate Buy$306.913.44% Upside
Labcorp Holdings Inc. stock logo
LH
Labcorp
2.79
Moderate Buy$276.087.38% Upside
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.639.78% Upside

Current Analyst Ratings Breakdown

Latest BMXMF, COR, NTRA, and LH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingCautious ➝ Cautious
6/25/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $275.00
6/11/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.00
6/3/2025
Cencora, Inc. stock logo
COR
Cencora
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$274.00 ➝ $337.00
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/12/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$274.00 ➝ $290.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
5/8/2025
Cencora, Inc. stock logo
COR
Cencora
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$330.00 ➝ $355.00
5/8/2025
Cencora, Inc. stock logo
COR
Cencora
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$314.00 ➝ $350.00
5/7/2025
bioMerieux stock logo
BMXMF
bioMerieux
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bioMerieux stock logo
BMXMF
bioMerieux
$4.31B3.91$4.48 per share31.79$38.50 per share3.70
Cencora, Inc. stock logo
COR
Cencora
$293.96B0.20$20.18 per share14.70$4.04 per share73.44
Labcorp Holdings Inc. stock logo
LH
Labcorp
$13.01B1.65$22.26 per share11.55$96.27 per share2.67
Natera, Inc. stock logo
NTRA
Natera
$1.70B13.53N/AN/A$9.05 per share18.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bioMerieux stock logo
BMXMF
bioMerieux
$467.68MN/A0.00N/AN/AN/AN/A9/4/2025 (Estimated)
Cencora, Inc. stock logo
COR
Cencora
$1.51B$8.6234.4217.581.450.55%344.71%4.26%7/30/2025 (Estimated)
Labcorp Holdings Inc. stock logo
LH
Labcorp
$746M$8.6529.7214.661.645.55%15.27%6.97%7/30/2025 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)

Latest BMXMF, COR, NTRA, and LH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
5/7/2025Q2 2025
Cencora, Inc. stock logo
COR
Cencora
$4.07$4.42+$0.35$3.68$75.41 billion$75.50 billion
4/29/2025Q1 2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bioMerieux stock logo
BMXMF
bioMerieux
N/AN/AN/AN/AN/A
Cencora, Inc. stock logo
COR
Cencora
$2.200.74%N/A25.52%15 Years
Labcorp Holdings Inc. stock logo
LH
Labcorp
$2.881.12%N/A33.29%N/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A

Latest BMXMF, COR, NTRA, and LH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/10/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
quarterly$0.721.25%5/29/20256/11/2025
5/8/2025
Cencora, Inc. stock logo
COR
Cencora
quarterly$0.550.8%5/16/20255/16/20256/2/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bioMerieux stock logo
BMXMF
bioMerieux
0.08
2.20
1.29
Cencora, Inc. stock logo
COR
Cencora
6.01
0.87
0.52
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.68
1.84
1.60
Natera, Inc. stock logo
NTRA
Natera
N/A
3.87
3.74

Institutional Ownership

CompanyInstitutional Ownership
bioMerieux stock logo
BMXMF
bioMerieux
N/A
Cencora, Inc. stock logo
COR
Cencora
97.52%
Labcorp Holdings Inc. stock logo
LH
Labcorp
95.94%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
bioMerieux stock logo
BMXMF
bioMerieux
N/A
Cencora, Inc. stock logo
COR
Cencora
10.80%
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.84%
Natera, Inc. stock logo
NTRA
Natera
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
bioMerieux stock logo
BMXMF
bioMerieux
14,600118.36 millionN/ANot Optionable
Cencora, Inc. stock logo
COR
Cencora
46,000193.82 million172.89 millionOptionable
Labcorp Holdings Inc. stock logo
LH
Labcorp
70,00083.70 million83.00 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
4,434136.55 million126.17 millionOptionable

Recent News About These Companies

3 Reasons We Love Natera (NTRA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
bioMerieux stock logo

bioMerieux OTCMKTS:BMXMF

$142.45 0.00 (0.00%)
As of 06/25/2025

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Cencora stock logo

Cencora NYSE:COR

$296.70 +4.38 (+1.50%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$296.54 -0.16 (-0.05%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Labcorp stock logo

Labcorp NYSE:LH

$257.12 -1.58 (-0.61%)
Closing price 06/26/2025 03:59 PM Eastern
Extended Trading
$256.89 -0.23 (-0.09%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Natera stock logo

Natera NASDAQ:NTRA

$168.17 +4.01 (+2.44%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$165.24 -2.93 (-1.74%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.